2 Reasons Pfizer Is on Our Minds Today
In this Market Foolery podcast, and with the big news coming out of healthcare, host Chris Hill calls upon the expert insight of Industry Focus: Healthcare host Kristine Harjes.
First, they consider the word that giant Pfizer (NYSE: PFE) is considering spinning off or selling its consumer healthcare business. Then they look ahead to earnings season, where Johnson & Johnson (NYSE: JNJ) and Pfizer will both provide some early interest, especially in the biologic-drug space. As a bonus, Kristine brings back a business insight or two among the souvenirs from her trip to Greece and offers a travel tip for anyone considering a similar vacation.
A full transcript follows the video.
Source: Fool.com
Johnson & Johnson Aktie
221,60 €
0,02 %
Einzigartige Zustimmung für Johnson & Johnson mit ausschließlich Buy-Einschätzungen.
Ein leicht positives Potenzial wird für Johnson & Johnson mit einem Kursziel von 228 € im Vergleich zu 221.6 € gesehen.
